文献速递系统性红斑狼疮

SMART-SLE:系统性红斑狼疮的血清学监测与重复检测——抗双链DNA监测分析

SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus-an analysis of anti-double-stranded DNA monitoring.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该研究基于跨国纵向队列2013至2021年3484例患者37582次就诊数据,按抗双链DNA结果分为持续阴性、波动和持续阳性三组。Cox回归显示,抗双链DNA比值>3及较前次就诊变化超过2倍均与后续复发风险升高相关,持续阳性组和波动组均如此,提示重复监测有临床价值。

要点

  • 持续抗双链DNA阳性患者占29.5%,波动者占34.3%。
  • 抗双链DNA比值>3时,持续阳性组复发调整HR为1.56,波动组为1.46。
  • 抗双链DNA较前次变化超过2倍时,波动组复发调整HR为1.33,持续阳性组为1.36。

核心结论

  • 抗双链DNA滴度的绝对值和变化均可预测复发,在持续抗双链DNA阳性患者中亦然,提示常规重复监测有临床价值。

研究设计与样本

  • 基于跨国纵向队列分析2013至2021年有已知抗双链DNA结果的患者数据,共纳入3484例患者37582次就诊。
  • 按抗双链DNA结果将患者分为持续阴性、波动和持续阳性三类,采用Cox回归模型分析抗双链DNA结果与复发的纵向关联。

主要发现

  • 3484例患者中,1029例(29.5%)为持续抗双链DNA阳性,1195例(34.3%)为波动结果。
  • 抗双链DNA以与正常 cut-off 的比值表示时,比值>3与后续复发风险相关:持续阳性组调整HR为1.56(95%CI:1.30,1.87;P<0.001),波动组调整HR为1.46(95%CI:1.28,1.66)。
  • 与上次就诊相比,抗双链DNA升高或降低超过2倍均与复发风险增加相关:波动组调整HR为1.33(95%CI:1.08,1.65;P=0.008),持续阳性组调整HR为1.36(95%CI:1.08,1.71;P=0.009)。

临床怎么用

  • 原文结论指出,抗双链DNA滴度的绝对值和变化可预测复发,包括持续抗双链DNA阳性患者,提示常规重复监测双链DNA有临床价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Disease activity monitoring in SLE includes serial measurement of anti-double stranded-DNA (dsDNA) antibodies, but in patients who are persistently anti-dsDNA positive, the utility of repeated measurement is unclear. We investigated the usefulness of serial anti-dsDNA testing in predicting flare in SLE patients who are persistently anti-dsDNA positive. METHODS: Data were analysed from patients in a multinational longitudinal cohort with known anti-dsDNA results from 2013 to 2021. Patients were categorized based on their anti-dsDNA results as persistently negative, fluctuating or persistently positive. Cox regression models were used to examine longitudinal associations of anti-dsDNA results with flare. RESULTS: Data from 37 582 visits of 3484 patients were analysed. Of the patients 1029 (29.5%) had persistently positive anti-dsDNA and 1195 (34.3%) had fluctuating results. Anti-dsDNA expressed as a ratio to the normal cut-off was associated with the risk of subsequent flare, including in the persistently positive cohort (adjusted hazard ratio [HR] 1.56; 95% CI: 1.30, 1.87; P < 0.001) and fluctuating cohort (adjusted HR 1.46; 95% CI: 1.28, 1.66), both for a ratio >3. Both increases and decreases in anti-dsDNA more than 2-fold compared with the previous visit were associated with increased risk of flare in the fluctuating cohort (adjusted HR 1.33; 95% CI: 1.08, 1.65; P = 0.008) and the persistently positive cohort (adjusted HR 1.36; 95% CI: 1.08, 1.71; P = 0.009). CONCLUSION: Absolute value and change in anti-dsDNA titres predict flares, including in persistently anti-dsDNA positive patients. This indicates that repeat monitoring of dsDNA has value in routine testing.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Yeo AL, Kandane-Rathnayake R, Koelmeyer R, et al. SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus-an analysis of anti-double-stranded DNA monitoring. Rheumatology (Oxford). 2024. PMID: 37208196. doi:10.1093/rheumatology/kead231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。